Avoid concomitant utilization of tucatinib with CYP3A substrates, exactly where negligible focus alterations might produce critical or lifestyle-threatening toxicities. If unavoidable, reduce CYP3A substrate dose As outlined by solution labeling.rufinamide will reduce the level or impact of triazolam by impacting hepatic/intestinal enzyme CYP3A4 me